|
1
|
Forastiere AA: Head and neck cancer:
Overview of recent developments and future directions. Semin Oncol.
27(Suppl 8): 1–4. 2000.PubMed/NCBI
|
|
2
|
Posner MR, Hershock DM, Blajman CR,
Mickiewicz E, Winquist E, Gorbounova V, Tjulandin S, Shin DM,
Cullen K, Ervin TJ, et al: TAX 324 Study Group: Cisplatin and
fluorouracil alone or with docetaxel in head and neck cancer. N
Engl J Med. 357:1705–1715. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Jie M, Ying L, Xi Y, et al: Induction
chemotherapy inpatients with resectable head and neck squamous cell
carcinoma: A Meta-analysis. World J Surg Oncol. 11:61–67.
2013.PubMed/NCBI
|
|
4
|
Pignon JP, Bourhis J, Domenge C and
Designé L: Chemotherapy added to locoregional treatment for head
and neck squamous-cell carcinoma: Three meta-analyses of updated
individual data. MACH-NC Collaborative Group. Meta-Analysis of
Chemotherapy on Head and Neck Cancer. Lancet. 355:949–955. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Monnerat C, Faivre S, Temam S, Bourhis J
and Raymond E: End points for new agents in induction chemotherapy
for locally advanced head and neck cancers. Ann Oncol. 13:995–1006.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Pignon JP, le Maître A, Maillard E and
Bourhis J; MACH-NC Collaborative Group: Meta-analysis of
chemotherapy in head and neck cancer (MACH-NC): An update on 93
randomised trials and 17,346 patients. Radiother Oncol. 92:4–14.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Glenny AM, Furness S, Worthington HV,
Conway DI, Oliver R, Clarkson JE, Macluskey M, Pavitt S, Chan KK
and Brocklehurst P; CSROC Expert Panel: Interventions for the
treatment of oral cavity and oropharyngeal cancer: Radiotherapy.
Cochrane Database Syst Rev. 4:CD0063872010.
|
|
8
|
Parmar MKB, Torri V and Stewart L:
Extracting summary statistics to perform meta-analyses of the
published literature for survival endpoints. Stat Med.
17:2815–2834. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
DerSimonian R and Laird N: Meta-analysis
in clinical trials. Control Clin Trials. 7:177–188. 1986.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Mitsudomi T, Hamajima N, Ogawa M and
Takahashi T: Prognostic significance of p53 alterations in patients
with non-small cell lung cancer: a meta-analysis. Clin Cancer Res.
6:4055–4063. 2000.PubMed/NCBI
|
|
11
|
Higgins JP, Thompson SG, Deeks JJ and
Altman DG: Measuring inconsistency in meta-analyses. BMJ.
327:557–560. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Armitage P, Berry G and Matthews JNS:
Analysing means and proportions. Statistical Methods in Medical
Research. 4th edition. Blackwell Science Ltd.; Hoboken, NJ; pp.
83–146. 2008
|
|
13
|
Olsen KD: Reexamining the treatment of
advanced laryngeal cancer. Head Neck. 32:1–7. 2010.PubMed/NCBI
|
|
14
|
Jarząb A, Grabarska A, Kiełbus M,
Jeleniewicz W, Dmoszyńska-Graniczka M, Skalicka-Woźniak K,
Sieniawska E, Polberg K and Stepulak A: Osthole induces apoptosis,
suppresses cell-cycle progression and proliferation of cancer
cells. Anticancer Res. 34:6473–6480. 2014.PubMed/NCBI
|
|
15
|
Dewyer NA, Wolf GT, Light E, Worden F,
Urba S, Eisbruch A, Bradford CR, Chepeha DB, Prince ME, Moyer J, et
al: Circulating CD4-positive lymphocyte levels as predictor of
response to induction chemotherapy in patients with advanced
laryngeal cancer. Head Neck. 36:9–14. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Bourhis J, Lefebvre JL, Temam S, Lusinchi
A, Janot F, Wibault P and Pignon JP: Laryngeal preservation:
nonsurgical approaches. Cancer Radiother. 8:S24–S28. 2004.(In
French). PubMed/NCBI
|
|
17
|
Pointreau Y, Lafond C, Legouté F,
Trémolières P, Servagi-Vernat S, Giraud P, Maingon P, Calais G and
Lapeyre M: Radiotherapy of larynx cancers. Cancer Radiother.
20:(Suppl):. S131–S135. 2016.(In French). View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Calais G, Chapet S, Ruffier-Loubière A and
Bernadou G: Induction chemotherapy for locally advanced head and
neck cancer. Cancer Radiother. 17:498–501. 2013.(In French).
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lévy A, Blanchard P, Janot F, Temam S,
Bourhis J, Daly-Schveitzer N and Tao Y: Results of definitive
radiotherapy for squamous cell carcinomas of the larynx patients
with subglottic extension. Cancer Radiother. 18:1–6. 2014.(In
French). View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Forastiere AA, Weber RS and Trotti A:
Organ Preservation for Advanced Larynx Cancer: Issues and Outcomes.
J Clin Oncol. 33:3262–3268. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Toohill RJ, Duncavage JA, Grossmam TW,
Malin TC, Teplin RW, Wilson JF, Byhardt RW, Haas JS, Cox JD,
Anderson T, et al: The effects of delay in standard treatment due
to induction chemotherapy in two randomized prospective studies.
Laryngoscope. 97:407–412. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Carew JF and Shah JP: Advances in
multimodality therapy for laryngeal cancer. CA Cancer J Clin.
48:211–228. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Gilbert J and Forastiere A: Organ
preservation trials for laryngeal cancer. Otolaryng Clin N Am.
35:1035–1054. 2002. View Article : Google Scholar
|
|
24
|
Gorphe P, Matias M, Even C, Ferte C,
Bidault F, Garcia G, Temam S, Nguyen F, Blanchard P, Tao Y, et al:
Laryngo-esophageal Dysfunction-free Survival in a Preservation
Protocol for T3 Laryngeal Squamous-cell Carcinoma. Anticancer Res.
36:6625–6630. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wolf GT, Fisher SG, Hong WK, Hillman R,
Spaulding M, Laramore GE, Endicott JW, McClatchey K and Henderson
WG; Department of Veterans Affairs Laryngeal Cancer Study Group:
Induction chemotherapy plus radiation compared with surgery plus
radiation in patients with advanced laryngeal cancer. N Engl J Med.
324:1685–1690. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zelefsky MJ, Kraus DH, Pfister DG, Raben
A, Shah JP, Strong EW, Spiro RH, Bosl GJ and Harrison LB: Combined
chemotherapy and radiotherapy versus surgery and postoperative
radiotherapy for advanced hypopharyngeal cancer. Head Neck.
18:405–411. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Richard JM, Sancho-Garnier H, Pessey JJ,
Luboinski B, Lefebvre JL, Dehesdin D, Stromboni-Luboinski M and
Hill C: Randomized trial of induction chemotherapy in larynx
carcinoma. Oral Oncol. 34:224–228. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Forastiere A, Goepfert H, Maor M, Pajak T,
Webwe R, Morrison W, et al: Concurrent chemotherapy and
radiotherapy for organ preservation in advanced laryngeal cancer. N
Engl J Med. 349:2091–2098. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Prades JM, Lallemant B, Garrel R, Reyt E,
Righini C, Schmitt T, Remini N, Saban-Roche L, Timoshenko AP,
Trombert B, et al: Randomized phase III trial comparing induction
chemotherapy followed by radiotherapy to concomitant
chemoradiotherapy for laryngeal preservation in T3M0 pyriform sinus
carcinoma. Acta Otolaryngol. 130:150–155. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Lefebvre JL, Andry G, Chevalier D,
Luboinski B, Collette L, Traissac L, de Raucourt D and Langendijk
JA; EORTC Head and Neck Cancer Group: Laryngeal preservation with
induction chemotherapy for hypopharyngeal squamous cell carcinoma:
10-year results of EORTC trial 24891. Ann Oncol. 23:2708–2714.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Forastiere AA, Zhang Q, Weber RS, Maor MH,
Goepfert H, Pajak TF, Morrison W, Glisson B, Trotti A, Ridge JA,
Thorstad W, et al: Long-term results of RTOG 91–11: a comparison of
three nonsurgical treatment strategies to preserve the larynx in
patients with locally advanced larynx cancer. J Clin Oncol.
31:8452013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Levy A, Blanchard P, Temam S, Maison MM,
Janot F, Mirghani H, Bidault F, Guigay J, Lusinchi A, Bourhis J, et
al: Squamous cell carcinoma of the larynx with subglottic
extension: Is larynx preservation possible? Strahlenther Onkol.
190:654–660. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Vandersteen C, Benezery K, Chamorey E,
Ettaiche M, Dassonville O, Poissonnet G, Riss JC, Pierre CS,
Hannoun-Lévi JM, Chand ME, et al: Contemporary therapeutic
management of locally advanced hypopharyngeal cancer: Oncologic and
functional outcomes - a report on 100 cases. Acta Otolaryngol.
135:193–200. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Lorch JH, Goloubeva O, Haddad RI, Cullen
K, Sarlis N, Tishler R, Tan M, Fasciano J, Sammartino DE and Posner
MR; TAX 324 Study Group: Induction chemotherapy with cisplatin and
fluorouracil alone or in combination with docetaxel in locally
advanced squamous-cell cancer of the head and neck: Long-term
results of the TAX 324 randomised phase 3 trial. Lancet Oncol.
12:153–159. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Lefebvre JL, Chevalier D, Luboinski B,
Kirkpatrick A, Collette L and Sahmoud T: Larynx preservation in
pyriform sinus cancer: preliminary results of a European
Organization for Research and Treatment of Cancer phase III trial.
EORTC Head and Neck Cancer Cooperative Group. Journal of the
National Cancer Institute. 8:890–899. 1996. View Article : Google Scholar
|
|
36
|
Lefebvre JL, Rolland F, Tesselaar M,
Bardet E, Leemans CR, Geoffrois L, Hupperets P, Barzan L, de
Raucourt D, Chevalier D, et al: EORTC Head and Neck Cancer
Cooperative Group; EORTC Radiation Oncology Group: Phase 3
randomized trial on larynx preservation comparing sequential vs
alternating chemotherapy and radiotherapy. J Natl Cancer Inst.
101:142–152. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Haddad R, O'Neill A, Rabinowits G, Tishler
R, Khuri F, Adkins D, Clark J, Sarlis N, Lorch J, Beitler JJ, et
al: Induction chemotherapy followed by concurrent chemoradiotherapy
(sequential chemoradiotherapy) versus concurrent chemoradiotherapy
alone in locally advanced head and neck cancer (PARADIGM): A
randomised phase 3 trial. Lancet Oncol. 14:257–264. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Su YX, Zheng JW, Zheng GS, Liao GQ and
Zhang ZY: Neoadjuvant chemotherapy of cisplatin and fluorouracil
regimen in head and neck squamous cell carcinoma: A meta-analysis.
Chin Med J (Engl). 121:1939–1944. 2008.PubMed/NCBI
|
|
39
|
Kumar B, Cordell KG, Lee JS, et al:
Response to Therapy and Outcome in Oropharyngeal Cancer are
Associated with Biomarkers Including HPV, EGFR, Gender and Smoking.
Int J Radiat Oncol Biol Phys. 69(Suppl 1): 1092007. View Article : Google Scholar
|
|
40
|
Calais G: TPF: a rational choice for
larynx preservation? Oncologist. 2010.15 Suppl 3 (. (15 Suppl 3):
19–24. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Wilken R, Veena MS, Wang MB and Srivatsan
ES: Curcumin: A review of anti-cancer properties and therapeutic
activity in head and neck squamous cell carcinoma. Mol Cancer.
10:122011. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Baumeister P, Reiter M and Harréus U:
Curcumin and Other Polyphenolic Compounds in Head and Neck Cancer
Chemoprevention. Oxid Med Cell Longev. 2012(902716)2012.PubMed/NCBI
|
|
43
|
Qiao Y, Gao K, Wang Y, Wang X and Cui B:
Resveratrol ameliorates diabetic nephropathy in rats through
negative regulation of the p38 MAPK/TGF-β1 pathway. Exp Ther Med.
13:3223–3230. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Ghalandarlaki N, Alizadeh AM and
Ashkani-Esfahani S: Nanotechnology-applied curcumin for different
diseases therapy. Biomed Res Int. 2014:3942642014. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Li L, Xu Y and Wang B: Liriodenine induces
the apoptosis of human laryngocarcinoma cells via the upregulation
of p53 expression. Oncol Lett. 9:1121–1127. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Wei Q, Yu D, Liu M, Wang M, Zhao M, Liu M,
Jia W, Ma H, Fang J, Xu W, et al: Genome-wide association study
identifies three susceptibility loci for laryngeal squamous cell
carcinoma in the Chinese population. Nat Genet. 46:1110–1114. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Liang W and Wang XF: In vitro induction of
specific anti-tumoral immunity against laryngeal carcinoma by using
human interleukin-12 gene-transfected dendritic cells. Chin Med J
(Engl). 124:1357–1361. 2011.PubMed/NCBI
|
